Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae

P S Moore, S J Gao, G Dominguez, E Cesarman, O Lungu, D M Knowles, R Garber, P E Pellett, D J McGeoch, Y Chang, P S Moore, S J Gao, G Dominguez, E Cesarman, O Lungu, D M Knowles, R Garber, P E Pellett, D J McGeoch, Y Chang

Abstract

Detection of novel DNA sequences in Kaposi's sarcoma (KS) and AIDS-related body cavity-based, non-Hodgkin's lymphomas suggests that these neoplasms are caused by a previously unidentified human herpesvirus. We have characterized this agent using a continuously infected B-lymphocyte cell line derived from an AIDS-related lymphoma and a genomic library made from a KS lesion. In this cell line, the agent has a large episomal genome with an electrophoretic mobility similar to that of 270-kb linear DNA markers during clamped homogeneous electric field gel electrophoresis. A 20.7-kb region of the genome has been completely sequenced, and within this region, 17 partial and complete open reading frames are present; all except one have sequence and positional homology to known gammaherpesvirus genes, including the major capsid protein and thymidine kinase genes. Phylogenetic analyses using both single genes and combined gene sets demonstrated that the agent is a gamma-2 herpesvirus (genus Rhadinovirus) and is the first member of this genus known to infect humans. Evidence for transient viral transmission from infected to uninfected cells is presented, but replication-competent virions have not been identified in infected cell lines. Sera from patients with KS have specific antibodies directed against antigens of infected cell lines, and these antibodies are generally absent in sera from patients with AIDS without KS. These studies define the agent as a new human herpesvirus provisionally assigned the descriptive name KS-associated herpesvirus; its formal designation is likely to be human herpesvirus 8.

References

    1. Curr Top Microbiol Immunol. 1990;154:125-69
    1. J Mol Biol. 1987 Nov 20;198(2):327-37
    1. Cancer Detect Prev. 1990;14(3):331-6
    1. J Mol Biol. 1990 Oct 5;215(3):403-10
    1. J Virol. 1991 Oct;65(10):5381-90
    1. Arch Virol. 1992;123(3-4):425-49
    1. J Exp Med. 1992 Jun 1;175(6):1663-8
    1. Cancer Surv. 1991;10:23-37
    1. J Virol. 1992 Aug;66(8):5047-58
    1. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7772-6
    1. Arch Virol. 1992;127(1-4):327-37
    1. Blood. 1993 Jun 15;81(12):3372-81
    1. J Virol. 1993 Jul;67(7):4093-103
    1. J Mol Biol. 1994 Apr 22;238(1):9-22
    1. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8
    1. Virology. 1988 Jun;164(2):334-40
    1. Annu Rev Genet. 1988;22:521-65
    1. J Gen Virol. 1989 Apr;70 ( Pt 4):837-55
    1. Lancet. 1990 Jan 20;335(8682):123-8
    1. Science. 1994 Dec 16;266(5192):1865-9
    1. Lancet. 1995 Mar 18;345(8951):722-3
    1. Lancet. 1995 Mar 25;345(8952):761-2
    1. N Engl J Med. 1995 May 4;332(18):1181-5
    1. N Engl J Med. 1995 May 4;332(18):1186-91
    1. N Engl J Med. 1995 May 4;332(18):1227-8
    1. J Mol Biol. 1995 Mar 31;247(3):443-58
    1. Lancet. 1995 Apr 22;345(8956):1043
    1. Lancet. 1995 Apr 22;345(8956):1043-4
    1. Lancet. 1995 May 6;345(8958):1180
    1. Science. 1995 Apr 28;268(5210):582-3
    1. Virology. 1995 May 10;209(1):29-51
    1. J Mol Biol. 1995 Jun 9;249(3):520-8
    1. Blood. 1995 Oct 1;86(7):2708-14
    1. Lancet. 1995 Sep 23;346(8978):799-802
    1. Nat Med. 1995 Jul;1(7):707-8
    1. Virus Res. 1995 Jun;37(1):55-62
    1. Acta Unio Int Contra Cancrum. 1962;18:330-63
    1. Arch Virol. 1990;113(1-2):53-60
    1. Nature. 1978 Mar 23;272(5651):373-5
    1. Anal Biochem. 1983 Jul 1;132(1):6-13
    1. Nature. 1984 Jul 19-25;310(5974):207-11
    1. J Gen Virol. 1984 Dec;65 ( Pt 12):2077-107
    1. Cell. 1986 Dec 26;47(6):883-9

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa